ArticleJournal of nanobiotechnology2021
Reactive oxygen species (ROS)-responsive nanoprobe for bioimaging and targeting therapy of osteoarthritis.
Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 69 citations in OpenAlex.
- Advances in drug delivery systems for Osteoarthritis therapy: exosomes, microparticles, nanoparticles, and hydrogels.Discover nano · 2026Review
- Smart Nanodelivery Systems for Immunometabolic Modulation in Osteoarthritis.Exploration (Beijing, China) · 2026Review
- Micro-nano integrated platforms for osteoarthritis therapy: From spatial manipulation to cellular reprogramming.Materials today. Bio · 2026Review
- Remodeling of senescent macrophages in synovium alleviates trauma- and aging-induced osteoarthritis.Bioactive materials · 2026Article
- Mitochondrial-targeted therapy for osteoarthritis: Challenges and opportunities from basic research to clinical translation.Frontiers in immunology · 2026Review
- ROS-scavenging nanomaterials as emerging tools for bone tissue regeneration: A comprehensive review of recent progress.Acta pharmaceutica Sinica. B · 2025Review
- Interactions Between Active Matters and Endogenous Fields.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Intelligent microstructure materials for diagnosis and treatment of osteoarthritis: progress and AI-enpowered future.Bone research · 2025Review
- Article
- Therapeutic Controlled Release Strategies for Human Osteoarthritis.Advanced healthcare materials · 2025Review
- Innovative Biotherapies and Nanotechnology in Osteoarthritis: Advancements in Inflammation Control and Cartilage Regeneration.International journal of molecular sciences · 2024Review
- Controlled Stimulus-Responsive Delivery Systems for Osteoarthritis Treatment.International journal of molecular sciences · 2024Review
- Promoting chondrogenesis by targeted delivery to the degenerating cartilage in early treatment of osteoarthritis.Bioactive materials · 2024Article
- PiRNA hsa_piR_019914 Promoted Chondrocyte Anabolic Metabolism By Inhibiting LDHA-Dependent ROS Production.Cartilage · 2024Article
- Heme oxygenase 1 linked to inactivation of subchondral osteoclasts in osteoarthritis.Journal of Zhejiang University. Science. B · 2024Article
- Stimulus-Responsive Nanodelivery and Release Systems for Cancer Gene Therapy: Efficacy Improvement Strategies.International journal of nanomedicine · 2024Review
- Functional Nanomaterials for the Treatment of Osteoarthritis.International journal of nanomedicine · 2024Review
- Reactive oxygen species (ROS)-responsive biomaterials for treating myocardial ischemia-reperfusion injury.Frontiers in bioengineering and biotechnology · 2024Review
- Advanced nanoparticles in osteoarthritis treatment.Biomaterials translational · 2024Review
- A smart hypochlorous acid fluorescent probe enabling Ibuprofen-release for osteoarthritis theranostics.Theranostics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Stimulus-responsive therapy that allows precise imaging-guided therapy is limited for osteoarthritis (OA) therapy due to the selection of proper physiological markers as stimulus. Based on that the over-production of Reactive Oxygen Species (ROS) is associated with the progression in OA, we selected ROS as markers and designed a cartilage targeting and ROS-responsive theranostic nanoprobe that can be used for effective bioimaging and therapy of OA. This nanoprobe was fabricated by using PEG micelles modified with ROS-sensitive thioketal linkers (TK) and cartilage-targeting peptide, termed TKCP, which was then encapsulated with Dexamethasone (DEX) to form TKCP@DEX nanoparticles. Results showed that the nanoprobe can smartly "turn on" in response to excessive ROS and "turn off" in the normal joint. By applying different doses of ROS inducer and ROS inhibitor, this nanoprobe can emit ROS-dependent fluorescence according to the degree of OA severity, helpful to precise disease classification in clinic. Specifically targeting cartilage, TKCP@DEX could effectively respond to ROS and sustained release DEX to remarkably reduce cartilage damage in the OA joints. This smart, sensitive and endogenously activated ROS-responsive nanoprobe is promising for OA theranostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.